AbbVie (NYSE:ABBV) Releases Q4 2026 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its fourth quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 3.830-3.870 for the period, compared to the consensus earnings per share estimate of 3.890. The company issued revenue guidance of $18.4 billion, compared to the consensus revenue estimate of $18.3 billion. AbbVie also updated its FY 2026 guidance to 13.950-13.990 EPS.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ABBV shares. Barclays upped their price objective on AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a research note on Wednesday, October 21st. Scotiabank raised their target price on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Weiss Ratings raised AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $275.00 price target on shares of AbbVie in a research report on Monday. Finally, Royal Bank Of Canada increased their price objective on AbbVie from $280.00 to $330.00 and gave the stock an “outperform” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $294.67.

AbbVie Stock Performance

Shares of NYSE ABBV traded down $0.72 during mid-day trading on Tuesday, hitting $288.12. 1,008,782 shares of the stock were exchanged, compared to its average volume of 6,315,951. AbbVie has a twelve month low of $190.75 and a twelve month high of $298.74. The stock’s fifty day simple moving average is $269.81 and its two-hundred day simple moving average is $237.57. The company has a market cap of $509.05 billion, a P/E ratio of 49.59, a PEG ratio of 1.31 and a beta of 0.24.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same period in the prior year, the company earned $1.86 EPS. AbbVie’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, equities research analysts predict that AbbVie will post 13.92 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. The ex-dividend date is Friday, January 15th. This is a boost from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is currently 119.10%.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its fiscal 2026 revenue outlook to $67.8 billion, above the $67.6 billion consensus, and set full-year adjusted EPS guidance of $13.95-$13.99. Q3 revenue increased 10.3% year over year to $17.4 billion, while adjusted EPS of $3.82 exceeded estimates. ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
• Positive Sentiment: Analysts responded by raising price targets, including Morgan Stanley to $346, Leerink Partners to $342, RBC to $330, Canaccord Genuity to $338 and Cantor Fitzgerald to $325, generally retaining positive ratings. Analysts Increase Forecasts on AbbVie
• Positive Sentiment: AbbVie expanded its global migraine-drug licensing partnership with Brise Pharmaceuticals. The agreement could be worth up to approximately $757 million and adds another potential growth asset to the neuroscience pipeline. AbbVie License Deal With Brise Potentially Valued at $757 Million
• Positive Sentiment: AbbVie won a lawsuit against the Department of Health and Human Services related to drug-price controls, potentially reducing near-term regulatory pricing pressure. The company also reported positive Phase 3 migraine-study news and continues to advance promising immunology candidates.
• Positive Sentiment: Allergan Aesthetics will present nine research abstracts at ASDS 2026, including studies involving post-medical-weight-loss aesthetic care and investigational trenibotulinumtoxinE, supporting AbbVie’s aesthetics pipeline and scientific positioning. Allergan Aesthetics Research at ASDS 2026
• Neutral Sentiment: AbbVie increased its quarterly dividend 5.2% to $1.82 per share, or $7.28 annualized, reinforcing its appeal to income-oriented investors.
• Negative Sentiment: Fourth-quarter revenue guidance of $18.4 billion is slightly above consensus, but adjusted EPS guidance of $3.83-$3.87 is below the $3.89 analyst estimate. In addition, shares have already gained roughly 33% this year and trade at a rich valuation, leaving less room for execution missteps. AbbVie Hit a New High After Earnings

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.